The International Vaccine Institute (IVI) said it was pleased to announce the receipt of a 1 million Euro grant from the German Federal Ministry of Education and Research (BMBF) for the Dengue Vaccine Initiative (DVI). This is the first time for it to receive such a grant from Germany. These funds will support the development of a new dengue vaccine through work with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam. Both Brazil and Vietnam have been greatly impacted by dengue. The vaccines currently in development at these institutions is a live attenuated tetravalent vaccine (LATV) candidate that has received licensure from the US National Institutes of Health (NIH). It contains four modified strains of the dengue virus. The first clinical studies of the vaccine have shown positive results, being both safe and immunogenic.
Full media release: http://www.denguevaccines.org/news-events/dengue-vaccine-initiative-awarded-grant-germany-development-new-dengue-vaccines-brazil-a

http://www.ivi.org/web/www/07_01?p_p_id=EXT_BBS&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_EXT_BBS_struts_action=%2Fext%2Fbbs%2Fview_message&_EXT_BBS_messageId=581